Structure Therapeutics Bolsa (NASDAQ: GPCR)

Últimas noticias sobre Structure Therapeutics (NASDAQ:GPCR) Bolsa

Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics Inc

Macro Economic Events

News

Econ #s

Economics

France Harmonised Index of Consumer Prices (MoM) For October 0.3% Vs. 0.3% Est.; -1.3% Prior

France Consumer Price Index (MoM) For October 0.3% Vs. 0.2% Est.; -1.3% Prior

OneStream, Inc announced today the pricing of the previously announced underwritten public offering of 15,000,000 shares of its Class&nbsp;A common stock, at a public offering price of $31.00 per share, of which 9,006,948 shares will be sold by selling stockholders and 5,993,052 shares will be sold by OneStream as part of a non-dilutive "synthetic secondary" transaction (the "Synthetic Secondary").

Reported Earlier, OneStream Prices Secondary Offering Of 15M Class A Common Stock At $31/Share

Associated expects to use the net proceeds from this offering for general corporate purposes to support continued organic growth and capital generation, which may include investments in Associated Bank, N.A. and potential balance sheet optimization strategies.

Reported Earlier, Associated Banc-Corp Prices $300M Public Offering Of 12M Common Stock Offering At $25/Share

In a unique perspective, a cryptocurrency analyst equated Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to gunpowder, arguing that sooner or later sovereign nations would be compelled to adopt the leading cryptocurrency.
What Happened: Matt Huang, CEO of cryptocurrency-focused investment firm Paradigm, penned a blog post Thursday, highlighting Bitcoin&#8217;s growing prominence. 
Huang argued that like gunpowder became indispensable after its discovery, the same would eventually pan out for emerging technologies like artificial intelligence, drones, and Bitcoin.
&#8220;Sovereigns can no longer afford to dismiss BTC. From a game theoretic perspective, BTC is like gunpowder, not the iPhone. Christopher,&#8221; the analyst remarked.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin for the Sovereign <a href="https://t.co/HD1UpcD6J7">pic.twitter.com/HD1UpcD6J7</a>
&mdash; Matt Huang (@matthuang) <a href="https://twitter.com/matthuang/status/1857127295145902586?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Huang highlighted how calls for the establishment of a Bitcoin strategic reserve have intensified since Donald Trump&#8217;s presidential victory, suggesting the opening of the Overton window for Bitcoin acceptance in America.
&#8220;Sovereigns that build BTC reserves early will benefit from significantly better entry prices. The race to build BTC reserves is on.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41912787/buckle-up-for-the-bull-markets-most-fun-phase-says-industry-expert-bitcoin-ethereum-dogecoin-about-to-enter-the-euphoria-stage?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Buckle Up&#8217; For The Bull Market&#8217;s &#8216;Most Fun Phase,&#8217; Says Industry Expert: Bitcoin, Ethereum, Dogecoin Abo</a>
Why It Matters: The Republican side vigorously promoted the idea of a Bitcoin reserve leading up to the elections, with none other than President-elect Trump <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40001426/trump-aims-to-make-us-crypto-capital-of-the-planet-well-get-it-done">vowing to establish one</a> if voted to power.
A few days later, Senator Cynthia Lummis (R-Wyo.) <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40087880/cynthia-lummis-unveils-strategic-bitcoin-reserve-legislation-this-is-our-louisiana-purchas">proposed </a>a bill, called the BITCOIN Act, aimed at creating a strategic Bitcoin stockpile to support America's balance sheet.
The senator reiterated her pledge following the Republican Party&#8217;s electoral triumph last week, as Polymarket odds showed a <a href="https://polymarket.com/event/will-trump-create-a-national-bitcoin-reserve-in-his-first-100-days?tid=1731494882651">35%</a> probability of this happening.
Moreover, emboldened by broader support, Pennsylvania introduced the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41986427/pennsylvania-introduces-bitcoin-strategic-reserve-act-to-invest-up-to-700-million-in-btc">Bitcoin Strategic Reserve Act</a>, hoping to build its own state-held Bitcoin reserve.
Price Action: At the time of writing, Bitcoin was trading at $87,824.55, down 2.35% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41998869/analyst-says-bitcoin-lives-rent-free-in-peoples-minds-after-peter-schiffs-cheeky-social-security-trust-remark">Peter Schiff&#8217;s Cheeky Bitcoin Turnaround Post Earns Reaction From Popular Analyst: &#8216;You Buy It And Become Rich Or You Keep Hating And Turn Crazy&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

Bitcoin Is Like Gunpowder And That Is Why Sovereign States Can't Refuse Its Adoption, Says Crypto Analyst

Buybacks

SNDL

Reported Earlier, SNDL Extends Share Repurchase Program With C$100M Authorization, Aiming To Repurchase Up To 13.2M Shares

Equus Total Return, Inc. (NYSE:<a href="https://www.benzinga.com/stock/EQS#NYSE">EQS</a>) ("Equus" or the "Company") reports net assets as of September 30, 2024, of $40.2 million. Net asset value per share decreased to $2.96 as of September 30, 2024, from $3.66 as of June 30, 2024. Comparative data is summarized below (in thousands, except per share amounts):&nbsp;&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>As of the Quarter Ended</td>
<td>9/30/2024</td>
<td>6/30/2024</td>
<td>3/31/2024</td>
<td>12/31/2023</td>
<td>9/30/2023 &nbsp;</td>
</tr>
<tr>
<td>Net assets</td>
<td>$40,165</td>
<td>$49,792</td>
<td>$45,892</td>
<td>$48,287</td>
<td>$47,128</td>
</tr>
<tr>
<td>Shares outstanding</td>
<td>13,586</td>
<td>13,586</td>
<td>13,586</td>
<td>13,586</td>
<td>13,518</td>
</tr>
<tr>
<td>Net assets per share</td>
<td>$2.96</td>
<td>$3.66</td>
<td>$3.38</td>
<td>$3.55</td>
<td>$3.49</td>
</tr>
</tbody>
</table>
</figure>

Reported Earlier, Equus Total Return Reports Net Assets As Of September 30, 2024, Of $40.2M; Net Asset Value Per Share $2.96

ZLAB

Reported Earlier, Zai Lab Prices 7.8M American Depositary Shares At $25.50/ADS In $200M Public Offering

Maui Land &amp; Pineapple Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLP#NYSE">MLP</a>) reported quarterly losses of $(0.07) per share. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported $3.02 million in sales this quarter. This is a 43.98 percent increase over sales of $2.10 million the same period last year.

Earnings

Maui Land & Pineapple Co Q3 EPS $(0.07) Down From $(0.06) YoY, Sales $3.02M Up From $2.10M YoY

GreenPower Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GP#NASDAQ">GP</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $5.347 million which missed the analyst consensus estimate of $7.967 million by 32.88 percent. This is a 36.35 percent decrease over sales of $8.400 million the same period last year.

Earnings Misses

GreenPower Motor Co Q2 2025 GAAP EPS $(0.18) Misses $(0.16) Estimate, Sales $5.347M Miss $7.967M Estimate

Beam Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.12) by 175 percent. The company reported quarterly sales of $11.482 million which missed the analyst consensus estimate of $18.863 million by 39.13 percent. This is a 30.35 percent decrease over sales of $16.486 million the same period last year.

Earnings Beats

BEEM

Beam Global Q3 2024 GAAP EPS $0.09 Beats $(0.12) Estimate, Sales $11.482M Miss $18.863M Estimate

Lantmännen will invest more than 100 million euros in a state-of–the-art <a href="https://www.globenewswire.com/Tracker?data=D-7Y-KVbP6QZknfadXEZ-FyiOL801tmcb6MoPLIt1GBtRzzMxYqB5y0WMAfkDOuP8wF9RdBMPWvDS7IIKC_OkWudCUCt9vi-8ARGYU9fdadf5aFadydlfMoC2c0oEek0wq9shl6f0tFxH4iEsBbG2plhHfhgHB7WME97-NbSZIM6dfFRmaj3AkU_gZXrXeRD6wSfFlbL5NZEKQdFWd05Ix8BUt1dMN_MHpAiD0GLnSSve8knOhEkT3alPDLqD0Z4qqemEbKkxRZ3MJ3oKFuKXBYY26VDZ92n-tTgubAPhQo=">factory in Sweden</a>, while partnering with Ingredion to develop a differentiated portfolio of plant-based protein isolates based on yellow peas. Construction of the production plant will be completed in 2027.

INGR

Reported Earlier, Ingredion And Lantmännen Forge Strategic Alliance To Boost European Plant-Based Protein Market, Invest Over €100M In New Pea Protein Facility

U.K. Trade Balance Non-EU For September -5.31B Vs. -4.85B (Revised) Prior

U.K. Trade Balance For September -16.32B Vs. -15.70B Est.; -15.21B (Revised) Prior

U.K. Monthly Gross Domestic Product (GDP) 3M/3M Change For September 0.1% Vs. 0.2% Est.; 0.2% Prior

U.K. Manufacturing Production (MoM) For September -1.0% Vs. 0.0% Est.; 1.3% (Revised) Prior

U.K. Industrial Production (MoM) For September -0.5% Vs. 0.1% Est.; 0.5% Prior

U.K. Gross Domestic Product (QoQ) Preliminary For Q3 0.1% Vs. 0.2% Est.; 0.5% Prior

U.K. Gross Domestic Product (YoY) Preliminary For Q3 1.0% Vs. 0.1% Est.; 0.7% Prior

U.K. Gross Domestic Product (MoM) For September -0.1% Vs. 0.2% Est.; 0.2% Prior

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Roche sees Carmot obesity drugs' potential peak sales at $3.6B+: report

Lilly looking to test Zepbound as health maintenance drug: report

Consumer, labor groups urge FTC to block Catalent sale to Novo Nordisk - report

In a report released today, Evan Seigerman from BMO Capital reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research ...

Evan Seigerman's Buy Rating Highlights Structure Therapeutics' Innovative Approach in Obesity Treatment Market

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and set a...

Piper Sandler Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Structure Therapeutics (GPCR) announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clin...

Structure Therapeutics doses first patients in ACCESS clinical study

Structure Therapeutics reports Q3 results

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has released its Q3 earnings. Here is a breakdown of the information Structure Therapeutics,...

Structure Therapeutics Reports Strong Q3 2024 Results

Jefferies analyst Roger Song maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and set a price t...

Jefferies Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

ALGS

AMEN

AMGN

CTLT

GPCR

MDGL

RHHBY

TERN

VKTX

Press Releases

Qiming's Nisa Leung Made the 2024 Forbes Midas List

IPOs

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Financing

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Health Care

Management

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

General

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

Comments

Structure Therapeutics

Noticias

Últimas noticias sobre Structure Therapeutics (NASDAQ:GPCR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL